NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
NRx Pharmaceuticals (NASDAQ:NRXP) and its wholly-owned subsidiary HOPE Therapeutics have announced their participation in two major healthcare conferences in February 2025. The company's Founder, Chairman and CEO, Dr. Jonathan Javitt, will present a company update at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025, from 9:20 to 9:50 AM EST.
The presentation will be available through a live webcast on the NRX Events section of the company's Investor Relations website, with replay access for 30 days post-event. Additionally, management will attend the 2025 BIO CEO & Investor Conference and will be available for one-on-one meetings in New York from February 10th-12th, 2025.
NRx Pharmaceuticals (NASDAQ:NRXP) e la sua sussidiaria interamente controllata HOPE Therapeutics hanno annunciato la loro partecipazione a due importanti conferenze sanitarie nel febbraio 2025. Il fondatore, presidente e CEO della società, il Dr. Jonathan Javitt, presenterà un aggiornamento aziendale al 35º Convegno Annuale Oppenheimer sulle Scienze della Vita e della Salute il 12 febbraio 2025, dalle 9:20 alle 9:50 AM EST.
La presentazione sarà disponibile tramite una diretta streaming nella sezione Eventi del sito web per le Relazioni con gli Investitori di NRX, con accesso alla registrazione per 30 giorni dopo l'evento. Inoltre, la direzione parteciperà al 2025 BIO CEO & Investor Conference e sarà disponibile per incontri individuali a New York dal 10 al 12 febbraio 2025.
NRx Pharmaceuticals (NASDAQ:NRXP) y su subsidiaria de propiedad total HOPE Therapeutics han anunciado su participación en dos importantes conferencias de salud en febrero de 2025. El fundador, presidente y CEO de la compañía, el Dr. Jonathan Javitt, presentará una actualización de la empresa en la 35ª Conferencia Anual Oppenheimer sobre Ciencias de la Vida y la Salud el 12 de febrero de 2025, de 9:20 a 9:50 AM EST.
La presentación estará disponible a través de una transmisión en vivo en la sección de Eventos del sitio web de Relaciones con Inversores de NRX, con acceso a la repetición durante 30 días después del evento. Además, la dirección asistirá a la Conferencia 2025 BIO CEO & Investor y estará disponible para reuniones uno a uno en Nueva York del 10 al 12 de febrero de 2025.
NRx Pharmaceuticals (NASDAQ:NRXP)와 그 전액 소유 자회사 HOPE Therapeutics는 2025년 2월 두 개의 주요 의료 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 창립자이자 회장, CEO인 Dr. Jonathan Javitt는 2025년 2월 12일 오전 9시 20분부터 9시 50분까지 Oppenheimer 제35회 연례 생명과학 및 보건 컨퍼런스에서 회사 업데이트를 발표할 예정입니다.
발표는 NRX 투자자 관계 웹사이트의 이벤트 섹션을 통해 생중계로 제공되며, 이벤트 후 30일 동안 다시 보기 가능하도록 제공됩니다. 또한 경영진은 2025 BIO CEO & Investor Conference에 참석할 예정이며, 2025년 2월 10일부터 12일까지 뉴욕에서 일대일 회의에 참석할 수 있습니다.
NRx Pharmaceuticals (NASDAQ:NRXP) et sa filiale entièrement détenue HOPE Therapeutics ont annoncé leur participation à deux grandes conférences sur la santé en février 2025. Le fondateur, président et CEO de l'entreprise, Dr. Jonathan Javitt, présentera une mise à jour de l'entreprise lors de la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie et la Santé le 12 février 2025, de 9h20 à 9h50 EST.
La présentation sera disponible via un webinaire en direct dans la section Événements du site Internet des Relations avec les Investisseurs de NRX, avec accès à la rediffusion pendant 30 jours après l'événement. De plus, la direction assistera à la Conférence 2025 BIO CEO & Investor et sera disponible pour des réunions individuelles à New York du 10 au 12 février 2025.
NRx Pharmaceuticals (NASDAQ:NRXP) und ihre hundertprozentige Tochtergesellschaft HOPE Therapeutics haben ihre Teilnahme an zwei wichtigen Gesundheitskonferenzen im Februar 2025 bekannt gegeben. Der Gründer, Vorsitzende und CEO des Unternehmens, Dr. Jonathan Javitt, wird am 12. Februar 2025 von 9:20 bis 9:50 Uhr EST ein Unternehmens-Update auf der 35. jährlichen Oppenheimer Healthcare Life Sciences Conference präsentieren.
Die Präsentation wird über einen Live-Stream im Abschnitt NRX Events der Investor Relations-Website des Unternehmens verfügbar sein, mit Zugriff auf die Aufzeichnung für 30 Tage nach der Veranstaltung. Darüber hinaus wird das Management an der 2025 BIO CEO & Investor Conference teilnehmen und in New York vom 10. bis 12. Februar 2025 für Einzelgespräche zur Verfügung stehen.
- None.
- None.
• Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in
The presentation is scheduled for Wednesday, February 12th, from 9:20 – 9:50 AM EST. A live webcast will be accessible on NRX Events, within the Investor Relations section of the Company's website. A replay of the webcast will also be available for 30 days following the event.
Management will also be available for one-on-one meetings in
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including risks arising from uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, HOPE Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off HOPE Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025-302369970.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
When is NRx Pharmaceuticals (NRXP) presenting at the Oppenheimer Healthcare Conference?
How can investors access NRXP's Oppenheimer Conference presentation?
What investor conferences is NRXP attending in February 2025?